



July 8, 2024

RE: Alinia[®], Anti-Diabetic Medications, and Pylera[®] Coverage Changes Effective July 22, 2024

The following changes will take effect July 22, 2024. Complete prior authorization (PA) criteria can be found on the OHCA website at www.oklahoma.gov/ohca/pa. Pharmacy PA forms can be found on the OHCA website at <https://oklahoma.gov/ohca/rxforms>.

Alinia[®]

Use of Alinia[®] (nitazoxanide) will require a PA. The Alinia[®] approval criteria are as follows:

1. An FDA approved indication for the treatment of diarrhea caused by *Giardia lamblia* or *Cryptosporidium parvum*; and
2. Member must be 12 years of age or older; and
3. For *Giardia*, member must have a recent trial of metronidazole or tinidazole or a patient-specific, clinically significant reason why the member cannot use metronidazole and tinidazole must be provided; and
4. A quantity limit of 6 tablets per 3 days will apply.

Anti-Diabetic Medications

Changes to the anti-diabetic medication tier chart include the following:

- Farxiga[®] (dapagliflozin) will be brand preferred. Members currently utilizing generic dapagliflozin will need to switch to brand Farxiga[®].
- Xigduo[®] XR (dapagliflozin/metformin ER) will be brand preferred. Members currently utilizing generic dapagliflozin/metformin ER will need to switch to brand Xigduo[®] XR.
- Saxagliptin (generic Onglyza[®]) and saxagliptin/metformin (generic Kombiglyze[®] and Kombiglyze XR[®]) will require PA for use. Members currently utilizing a saxagliptin product will be approved for continued therapy.
- Insulin degludec (unbranded Tresiba[®]) will require PA for use. Members currently utilizing insulin degludec will need to switch to brand Tresiba[®].
- Insulin glargine U-300 (unbranded Toujeo[®]) will require PA for use. Members currently utilizing insulin glargine U-300 will need to switch to brand Toujeo[®].
- Insulin glargine-yfgn (generic Semglee[®]) will be available without PA.

As a reminder, higher-tiered GLP-1 agonists will not be authorized solely due to shortage or supply issues of the member's current GLP-1 agonist. Tier-2 GLP-1 agonists or Tier-1 or Tier-2 DPP-4 inhibitors should be considered when appropriate. The specific PA requirements and tier chart for the anti-diabetic medications are located on the OHCA website at www.oklahoma.gov/ohca/pa in the "Diabetes/Endocrine" therapeutic category.

Pylera[®]

Pylera[®] (bismuth subcitrate potassium/metronidazole/tetracycline) will no longer be brand preferred. Members will need to use the individual ingredients or submit a PA request for consideration of use.

The specific PA requirements and tier chart for the anti-ulcer medications are located on the OHCA website at www.oklahoma.gov/ohca/pa in the "Gastrointestinal" therapeutic category.

Thank you for the services you provide to Oklahomans insured by SoonerCare!

SOONERCARE PHARMACY SERVICES • PHARMACY MANAGEMENT CONSULTANTS



ADDRESS

4345 N. Lincoln Blvd.
Oklahoma City, OK 73105



WEBSITES

oklahoma.gov/ohca
mysoonerCare.org



PHONE

Admin: 405-522-7300
Helpline: 800-987-7767